Abstract
Lung squamous-cell carcinoma (SqCC) is the second most common histology in non-small-cell lung carcinomas (NSCLCs). The treatment options for advanced lung SqCC are still an unmet medical need. Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), is beneficial in the therapy of advanced NSCLC patients. This study aimed to preliminarily assess the efficacy and safety of low-dosage apatinib in patients with advanced lung SqCC. In this single-arm, open-label, investigator-initiated phase II prospective study (ChiCTR1800019808), we enrolled patients aged 54-80 years with platinum-refractory or chemotherapy rejected advanced lung squamous-cell carcinoma. Key exclusion criteria included major blood vessel involvement and gross hemoptysis with an amount of more than 20 mL. Apatinib at an initial dose of 250 mg was administered to patients once daily until disease progression, unacceptable toxicity, withdrawal, or death. The primary endpoint was progression-free survival (PFS) in all patients. We assessed the adverse events according to the treatment received. Thirty-eight patients were enrolled between June 11, 2015 and August 29, 2018. Two patients failed to evaluate treatment efficacy for ...Continue Reading
References
Nov 18, 1971·The New England Journal of Medicine·J Folkman
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H JohnsonFairooz Kabbinavar
Dec 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J Hicklin, Lee M Ellis
Jun 22, 2005·The Oncologist·Lee S Rosen
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan B SandlerDavid H Johnson
Dec 25, 2009·Japanese Journal of Clinical Oncology·Tetsuya Mitsudomi
Nov 8, 2011·Clinics in Chest Medicine·Charles S Dela CruzRichard A Matthay
Aug 7, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jin LiHao Yu
Mar 8, 2014·International Journal of Cancer. Journal International Du Cancer·Xichun HuChunmei Liao
Jun 17, 2014·Lancet·Edward B GaronMaurice Pérol
Feb 18, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jin LiHao Yu
May 20, 2016·Medicine·Lin DingHe-Rui Yao
Jun 12, 2016·Pharmacology & Therapeutics·Beverly L FalconBronislaw Pytowski
Aug 6, 2016·Oncotarget·Chen LinJianhua Chang
Apr 4, 2017·OncoTargets and Therapy·Zhengbo SongYiping Zhang
Sep 6, 2017·Journal of Hematology & Oncology·Xinyang LiuJin Li
Oct 17, 2017·Oncotarget·Da-Xiong ZengJun-Hong Jiang
Dec 14, 2018·Cancer Chemotherapy and Pharmacology·Da-Xiong ZengJun-Hong Jiang